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A b s t r a c t
Introduction: Extended immunosuppressive treatment in patients after 
heart transplantation modifies etiopathogenesis and occurrence of many 
diseases in this population. The aim of the present study was to evaluate 
the frequency and to define risk factors for cholelithiasis after heart trans-
plantation (HTX).
Material and methods: The study population consisted of 176 subjects. Of 
them, 24 patients (group A) presented with symptomatic cholelithiasis. An-
other group of 24 patients without cholelithiasis (group B) served as con-
trols. Both groups were similar with respect to age, gender and follow-up af-
ter the transplant. Clinical interview, surgical and hospitalization data were 
collected from medical records.
Results: The groups did not differ in demographic features. There were sta-
tistical differences (p < 0.05) between group A and B in rejection reaction, 
doses of immunosuppressive drugs, type 2 diabetes, serum lipid disorders 
and acute rejection episodes. These events were caused by modification of 
treatment, especially the immunosuppressive regimen. Group A  consisted 
of 75% men and 25% women. The frequency of symptomatic cholelithiasis 
was 11.7% in men and 27.3% in women, on average 19.5%. Mean time to 
cholelithiasis following HTX was 37.9 ±4.9 (Me = 41.5) months, 27.7 ±8.2 
(Me = 30.0) months in women and 41.3 ±5.9 (Me = 41.5) months in men. 
The female to male ratio was 2.3 : 1.
Conclusions: Cholelithiasis following HTX was significantly more frequent as 
compared with the non-transplant population. Patients with cholelithiasis 
required more aggressive immunosuppression because of more frequent ep-
isodes of acute transplant rejection. Patients with cholelithiasis significantly 
more frequently showed increased glycemia and blood lipids, which could be 
the side effect of intensive immunosuppressive therapy.
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Introduction
Heart transplantation (HTX) nowadays is still the most effective treat-
ment of patients with end-stage heart failure with a  “bad prognosis” 
[1–3]. Management of the patient after heart transplantation is a chal-
lenge and requires collaboration between physicians of different special-
ties. Immunosuppressants in high doses and their side-effects amplify 
the effects of coexistent risk factors such as cholelithiasis, nephrolithi-
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asis, diabetes, atherosclerosis, deep vein throm-
bosis and others [4]. Increased morbidity due to 
cholelithiasis observed in patients following HTX 
probably results from disadvantageous effects of 
immunosuppressive treatment in those patients 
who require higher doses of medicines because of 
the severity of transplant rejection. Decreased im-
munity in these patients increases the likelihood 
of acute septic complications of cholelithiasis, 
shifting the patients to a high-risk group charac-
terized by a particularly high probability of compli-
cation and death.
The aim of the study is to evaluate the frequen-
cy of cholelithiasis and to define risk factors for 
developing cholelithiasis after HTX.
Material and methods
Patient population
A group of 176 patients (M = 154 (87.5%), F = 22 
(12.5%)), over 40 years of age, operated on be-
tween 1996 and 2005, was identified. Of them, 
24 with symptomatic cholelithiasis were includ-
ed in the retrospective analysis (group A). Pa-
tients operated on before the year 1996 were 
excluded from the analysis because of incom-
plete data (abdominal ultrasound, echo data and 
details of immunosuppression protocols). The pa- 
 tients in group A did not have significant gall-
stones before heart transplantation – data con-
firmed by abdominal USG done routinely be-
fore HTX. Another group of 24 patients without 
cholelithiasis (group B) served as controls. Both 
groups were similar with respect to age, gender 
and follow-up after the transplant. Abdominal 
ultrasound was used to confirm (group A) or ex-
clude (group B) the presence of cholelithiasis. 
Clinical interview, surgical and hospitalization 
data were collected from medical records.
Patient management
All patients in both groups were treated with 
cyclosporine, and either azathioprine or myco-
phenolate mofetil. All doses of medicines and 
administration of azathioprine (AZA) or myco-
phenolate mofetil (MMF) were tailored for each 
patient depending on the severity of transplant 
rejection. Steroids were given transiently in case 
of acute rejection and clinical deterioration of 
the patient. 
Statistical analysis
Groups A and B were compared with respect 
to body mass index (BMI), coexisting lipid disor-
ders, type 2 diabetes, average immunosuppres-
sant doses (cyclosporine, MMF, AZA), as well 
as the number and transplant rejection grade. 
There were no cases of type 1 diabetes. 
All data are presented as means ± SE (stan-
dard error) unless otherwise indicated. For com-
parisons between group A  and B of the cross- 
sectional study, the Shapiro-Wilk test was 
performed (for estimating normal distribution), 
then either Student’s t-test (for equal varianc-
es) or Cochran-Cox’s test (for different varianc-
es) was used for data analysis. Homogeneity 
of variance was checked by Levene’s test. The 
χ2 test was used for analysis of BMI and the 
Kruskal-Wallis test for multivariable analysis of 
ISHLT grade. Standard deviation (SD) and me-
dian (Me) were also calculated. All statistical 
analyses were performed using the statistical 
software package Statistica (StatSoft, Inc. Tul-
sa, Oklahoma). We also used the Kaplan-Mei-
er curve to analyze the long-term survival and 
log-rank test for comparing survival differences 
between groups of patients.  
Results
General data
In group A, there were 16 men and 6 women 
(M : F = 3 : 1). The average age was 56 years. 
Symptomatic cholelithiasis was observed in 
27.3% of women (6 cases out of 22) and in 11.7% 
of men (18 cases out of 154), thus 2.3 times more 
often in women than in men. The average rate of 
cholelithiasis was 19.5%. Mean time to cholelithi-
asis following HTX was 37.9 ±4.9 (Me = 41.5) 
months, 27.7 ±8.2 (Me = 30.0) months in women 
and 41.3 ±5.9 (Me = 41.5) months in men.
Symptomatology
The main symptom of cholelithiasis was biliary 
colic, which was observed in 79.2% of patients 
(19 out of 24), all of them being women in group 
A. Dyspepsia, defined as a  “small symptom of 
cholelithiasis” was reported by 45.8% of patients 
(11 out of 24), but complications of cholelithiasis 
developed in about 33.3% of patients (8 out of 24). 
The complications were 3 times more frequent in 
women than in men, i.e. 66.7% (4 of 6) vs. 22.2% 
(4 of 18). In all patients in the study group, at least 
2 out of 3 symptoms appeared. All patients with 
complications underwent cholecystectomy.
Cholecystectomy
Generally, 45.8% (11 of 24) of patients in the 
study group underwent cholecystectomy, includ-
ing 66.7% of women (4 of 6) and 38.9% of men 
(7 of 18). Conventional and laparoscopic cholecys-
tectomy was performed in 8 (62.7%) and 3 pa tients 
(27.3%), respectively. Mean time from trans-
plantation to cholecystectomy was 42.6 ±8.7 
(Me = 38.0) months. In women, this interval was 
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two times shorter (24.5 ±10.6 months) (Me = 23.0) 
than in men (53 ±10.9 months) (Me = 46.0) (Ta-
bles I A and B).
Based on our observations, MMF instead of 
AZA effectively lowered inflammatory reactions 
in patients after HTX (group A). Mycophenolate 
mofetil allowed for use of a  statistically lower 
(p = 0.024) dose of cyclosporine (average: 2.93 
±0.35 mg/kg b.m.) when administered in combi-
nation with MMF. The mean dose of cyclospo-
rine in connection with AZA was higher (aver-
age: 3.41 ±0.45 mg/kg b.m.).
With time, azathioprine was replaced by my-
cophenolate mofetil, resulting in the lowering of 
cyclosporine A (CsA) doses [5–10].
Long-term survival
Patients were followed up for 16 years after 
heart transplant. At the same time of obser-
vation a  group of patients with cholelithiasis 
revealed a  worse survival rate. Fourteen of 24 
(58.3%) patients survived in comparison to the 
control group in which 16 of 24 (66.6%) patients 
survived. There was no statistically significant 
difference between A and B (p = 0.37) (Figure 1).
Discussion
In the study group, the increased frequency 
of symptomatic cholelithiasis after HTX (19.5% 
on average vs. 2.4% in general population) was 
probably associated with high doses of immu-
nosuppressants – CsA and AZA [11]. The com-
plex of cyclosporine binding with cyclophilin 
decreases the activity of T cells by inhibiting 
calcineurin, which is responsible for activation of 
interleukin 2. The reduced level of IL-2 leads to 
deteriorating function of T cells. Azathioprine is 
a pro-drug for 6-mercaptopurine. It blocks purine 
metabolism and DNA synthesis and strongly af-
fects T and B proliferating cells. Immunosuppres-
sants increased the risk of cholelithiasis, which 
developed more frequently in these patients 
as compared with the general population. The 
Table I. Cholelithiasis risk factors 
Group Body mass index Lipid disturbances
Norm Overweight Obesity HC < 1 year HTG < 1 year HC > 1 year HTG > 1 year
A 3/24
(11.7%)
17/24
(70.8%)
4/24
(16.7%)
7/24
(29.2%)
6/24
(25.0%)
17/24
(70.8%)
16/24
(66.7%)
B 11/24
(45.4%)
12/24
(50.0%)
1/24
(4.2%)
5/24
(20.8%)
7/24
(29.2%)
5/24
(20.8%)
7/24
(29.2%)
Value of p 0.01 0.76 0.16 0.51 0.75 0.002 0.009
HC – hypercholesterolemia, HTG – hypertriglyceridemia
Group Diabetes 
type 2
ISHLT
Gr < 1 year
ISHLT
Gr > 1 year
CsA (SD) MMF (SD) AZA (SD)
A 3/24
(11.7%)
0 – 11/24 (45.4%)
1A – 10/24 (41.7%)
3A – 3/24 (11.7%)
0 – 11/24 (45.4%)
1A – 8/24 (33.3%)
1B – 4/24 (16.7%)
2A – 1/24 (4.2%)
3.17 ±0.36 28.9 ±17.3 1.083 ±0.18
B 1/24
(4.2%)
0 – 17/24 (70.8%)
1A – 4/24 (16.7%)
1B – 3/24 (11.7%)
0 – 24/24 (100%) 2.45 ±0.54 23.5 ±3.3 0.95 ±0.1
Value of p 0.30 0.19 < 0.001 < 0.001 0.49 0.039
ISHLT Gr – The International Society for Heart and Lung Transplantation System for Grading Rejection, CsA – cyclosporine A average 
doses (mg/kg b.m.), MMF – mycophenolate mofetil average doses (mg/kg b.m.), AZA – azathioprine average doses (mg/kg b.m.)
Figure 1. Kaplan-Meier curve: long-term surviving 
proportion between group A and group B. Log-rank 
test statistic = –0.905054, p = 0.36544
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following risk factors were statistically signifi-
cant in group A: gender (2.3 times more frequent 
in women), obesity, diabetes mellitus type 2 and 
lipid disorders (the higher frequency of lipid dis-
orders at long-term follow-up in group A  was 
probably associated with the adverse side ef-
fects of immunosuppressants), higher rejection 
grade according to the ISHLT scale, and a neces-
sity of using higher doses of CsA and AZA.
Prolonged immunosuppression after HTX 
is associated with progression of risk factors, 
which intensify the process of cholelithiasis 
[12]. Cholelithiasis could escalate in an immune 
response and inflammatory state, thus intensi-
fying the transplant rejection.
Available evidence [13] shows that adminis-
tration of MMF instead of AZA significantly re-
duces the inflammatory state in patients after 
HTX. Mycophenolate mofetil is a reversible inhib-
itor of monophosphate dehydrogenase (IMPDH). 
This enzyme is important in purine biosynthesis 
and maturation of T cells. Mycophenolate mofetil 
does not cause chromosomal aberrations, and 
thus shows a less mutagenic effect in comparison 
to azathioprine [14]. Mycophenolate mofetil gen-
erates less frequent side effects. Administration 
of MMF provides a  possibility of reducing cyc-
losporine doses, which probably delays the pro-
cess of cholelithiasis. Therefore, there is a prob-
ability that in patients with active cholelithiasis, 
treated with MMF, the risk of acute transplant 
rejection can be diminished through reducing 
the inflammatory state (decreasing the unfavor-
able positive feedback effect).
On the other hand, immunosuppressive agents 
used to suppress the inflammatory response, 
due to reduction in the number of resistant cells 
(the side effect of immunosuppression), con-
tribute to the masking of the presence of the 
inflammatory process in patients with active 
cholelithiasis. It poses a  serious risk of diag-
nosing the disease at a late stage. Furthermore, 
cholelithiasis in the general population is asso-
ciated with risk of gallbladder cancer. Neoplasm 
in patients after organ transplantation who are 
on immunosuppression is one of the most fre-
quent causes of death [15].
The present study suggests that patients af-
ter HTX should be monitored for the presence 
of biliary tract disease. Regular clinical exam-
inations, abdominal ultrasound, and laboratory 
tests (CRP, ESR, leukocytosis) as a standard pro-
cedure allow for early diagnosis and avoidance 
of further complications [16–20]. This could 
increase long-term survival and potentially im-
prove the quality of life [21] in patients after 
heart transplantation.
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